title: Linking research to global health equity: the contribution of product development partnerships to access to medicines and research capacity building.
abstract: Certain product development partnerships (PDPs) recognize that to promote the reduction of global health disparities they must create access to their products and strengthen research capacity in developing countries. We evaluated the contribution of 3 PDPs--Medicines for Malaria Venture, Drugs for Neglected Diseases Initiative, and Institute for One World Health--according to Frost and Reich's access framework. We also evaluated PDPs' capacity building in low- and middle-income countries at the individual, institutional, and system levels. We found that these PDPs advance public health by ensuring their products' registration, distribution, and adoption into national treatment policies in disease-endemic countries. Nonetheless, ensuring broad, equitable access for these populations--high distribution coverage; affordability, particularly for the poor; and adoption at provider and end-user levels--remains a challenge.
authors.affiliation: The authors are with the Michael Kirby Centre for Public Health and Human Rights, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
authors.forename: Bridget
authors.initials: B
authors.lastname: Pratt
authors.forename: Bebe
authors.initials: B
authors.lastname: Loff
mesh_terms: D057191:Capacity Building; D003906:Developing Countries; D014943:Global Health; D006297:Health Services Accessibility; D054625:Healthcare Disparities; D006801:Humans; D008288:Malaria / Q000188:drug therapy; D058069:Neglected Diseases / Q000188:drug therapy; D004364:Pharmaceutical Preparations / Q000191:economics / Q000600:supply & distribution*; D055818:Public-Private Sector Partnerships; D012106:Research
chemical_list: D004364:Pharmaceutical Preparations
references.citation: PLoS Med. 2005 Sep;2(9):e302
references.pmid: 16138789
references.citation: PLoS Med. 2011 Feb;8(2):e1000411
references.pmid: 21408102
references.citation: Health Res Policy Syst. 2011 Mar 31;9:15
references.pmid: 21453529
references.citation: Bull World Health Organ. 2004 Oct;82(10):764-70
references.pmid: 15643798
references.citation: Science. 2008 May 23;320(5879):1016-7
references.pmid: 18497279
references.citation: PLoS One. 2010 May 12;5(5):e10610
references.pmid: 20485552
references.citation: Malar J. 2011 Feb 10;10:34
references.pmid: 21310057
references.citation: Clin Infect Dis. 2002 Dec 15;35(12):1469-76
references.pmid: 12471565
references.citation: Lancet. 2010 Mar 27;375(9720):1080
references.pmid: 20346811
references.citation: Lancet. 2010 Apr 24;375(9724):1457-67
references.pmid: 20417857
references.citation: Malar J. 2011 May 23;10:143
references.pmid: 21605364
references.citation: Lancet. 2009 Jul 4;374(9683):56-64
references.pmid: 19559476
references.citation: Int Health. 2010 Jun;2(2):114-22
references.pmid: 24037470
references.citation: Bull World Health Organ. 2012 Jan 1;90(1):55-62
references.pmid: 22271965
references.citation: PLoS Negl Trop Dis. 2010 May 25;4(5):e720
references.pmid: 20520803
references.citation: Health Res Policy Syst. 2011 Aug 26;9:33
references.pmid: 21871103
references.citation: Lancet Infect Dis. 2007 Jan;7(1):56-61
references.pmid: 17182344